AngioDynamics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van AngioDynamics is gedaald met een gemiddeld jaarlijks percentage van -14.4%, terwijl de winst van de Medical Equipment -industrie jaarlijks groeide met 12%. De inkomsten zijn groeide met een gemiddeld percentage van 4.3% per jaar.

Belangrijke informatie

-14.4%

Groei van de winst

-12.6%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie	8.9%
Inkomstengroei	4.3%
Rendement op eigen vermogen	-123.6%
Nettomarge	-83.0%
Laatste winstupdate	31 Aug 2024

Recente prestatie-updates uit het verleden

Recent updates

AngioDynamics, Inc. (NASDAQ:ANGO) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Jul 19

Improved Revenues Required Before AngioDynamics, Inc. (NASDAQ:ANGO) Stock's 26% Jump Looks Justified

Jul 18

AngioDynamics: A Story To Monitor

May 14

A Leaner AngioDynamics Is A High-Risk Execution-Driven Story

Apr 09

AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry

Apr 06

AngioDynamics: Restructuring Initiative May Not Go Far Enough

Jan 14

AngioDynamics (NASDAQ:ANGO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Oct 12

AngioDynamics (NASDAQ:ANGO) Is Carrying A Fair Bit Of Debt

Mar 31

AngioDynamics Non-GAAP EPS of -$0.06 misses by $0.04, revenue of $81.5M misses by $1.93M, reaffirms FY guidance

Oct 06

Opbrengsten en kosten

Hoe AngioDynamics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:ANGO Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
31 Aug 24	293	-243	143	30
31 May 24	304	-184	144	31
29 Feb 24	324	-192	146	32
30 Nov 23	330	-14	144	31
31 Aug 23	336	6	146	29
31 May 23	339	-52	144	30
28 Feb 23	335	-37	146	30
30 Nov 22	328	-33	144	31
31 Aug 22	321	-33	140	32
31 May 22	316	-27	134	30
28 Feb 22	306	-40	133	32
30 Nov 21	303	-38	130	33
31 Aug 21	298	-34	126	34
31 May 21	291	-32	117	36
28 Feb 21	273	-169	112	34
30 Nov 20	271	-171	114	33
31 Aug 20	268	-170	116	32
31 May 20	264	-167	117	30
29 Feb 20	277	-7	120	29
30 Nov 19	273	-6	116	28
31 Aug 19	273	-7	113	27
31 May 19	271	-11	112	28
28 Feb 19	205	-34	107	27
30 Nov 18	223	-16	106	26
31 Aug 18	240	-12	103	25
31 May 18	262	-6	104	24
28 Feb 18	343	1	108	25
30 Nov 17	345	-10	108	25
31 Aug 17	347	4	109	25
31 May 17	270	-7	106	24
28 Feb 17	356	-25	109	26
30 Nov 16	358	-27	111	25
31 Aug 16	357	-42	113	26
31 May 16	351	-44	114	25
29 Feb 16	347	-1	116	25
30 Nov 15	346	-6	115	26
31 Aug 15	349	-5	114	26
31 May 15	352	-3	112	27
28 Feb 15	356	-4	111	26
30 Nov 14	358	5	112	27
31 Aug 14	354	4	111	27
31 May 14	351	2	112	28
28 Feb 14	346	2	108	27
30 Nov 13	340	-3	105	26

Kwaliteitswinsten: ANGO is momenteel verliesgevend.

Groeiende winstmarge: ANGO is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: ANGO is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 14.4% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van ANGO over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: ANGO is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Medical Equipment industrie ( 10.4% ).

Rendement op eigen vermogen

Hoge ROE: ANGO heeft een negatief Return on Equity ( -123.63% ), omdat het momenteel verliesgevend is.

AngioDynamics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

First quarter 2025 earnings: EPS misses analyst expectations

AngioDynamics, Inc. to Report Q1, 2025 Results on Oct 03, 2024

Full year 2024 earnings: EPS in line with analyst expectations despite revenue beat

AngioDynamics, Inc. to Report Q4, 2024 Results on Jul 16, 2024

AngioDynamics, Inc. to Report Q3, 2024 Results on Apr 04, 2024

AngioDynamics, Inc. to Report Q2, 2024 Results on Jan 05, 2024

Recent updates

AngioDynamics, Inc. Announces the Launch of an International Multi-Center Prospective Registry Study

CEO, President & Director recently bought US$121k worth of stock

Consensus EPS estimates fall by 16%

No longer forecast to breakeven

First quarter 2025 earnings: EPS misses analyst expectations

AngioDynamics, Inc. Provides Earnings Guidance for the Year 2025

New minor risk - Shareholder dilution

AngioDynamics, Inc., Annual General Meeting, Nov 12, 2024

AngioDynamics, Inc. to Report Q1, 2025 Results on Oct 03, 2024

Consensus EPS estimates upgraded to US$0.81 loss

AngioDynamics, Inc. (NASDAQ:ANGO) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Improved Revenues Required Before AngioDynamics, Inc. (NASDAQ:ANGO) Stock's 26% Jump Looks Justified

Full year 2024 earnings: EPS in line with analyst expectations despite revenue beat

Forecast to breakeven in 2027

AngioDynamics, Inc. (NasdaqGS:ANGO) announces an Equity Buyback for $15 million worth of its shares.

AngioDynamics, Inc. to Report Q4, 2024 Results on Jul 16, 2024

AngioDynamics: A Story To Monitor

CEO, President & Director recently bought US$67k worth of stock

A Leaner AngioDynamics Is A High-Risk Execution-Driven Story

AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry

Price target decreased by 10.0% to US$13.50

Insufficient new directors

AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2024

Angiodynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc

AngioDynamics, Inc. to Report Q3, 2024 Results on Apr 04, 2024

Angiodynamics, Inc. Announces Board Changes

Angiodynamics Announces FDA 510(K) Clearance of Auryon Xl Radial Access Catheter to Treat Peripheral Arterial Disease

AngioDynamics: Restructuring Initiative May Not Go Far Enough

AngioDynamics, Inc. Announces Manufacturing Operations Restructuring

David D. Helsel to Leave AngioDynamics, Inc. as Senior Vice President of Global Operations and R&D, Effective January 12, 2024

AngioDynamics, Inc. to Report Q2, 2024 Results on Jan 05, 2024

AngioDynamics, Inc. Completes Patient Enrollment in Apex-Av Study Assessing Alphavac F1885 System in Treatment of Pulmonary Embolism

AngioDynamics (NASDAQ:ANGO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Angiodynamics, Inc. Provides Earning Guidance for Fiscal Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

AngioDynamics, Inc., Annual General Meeting, Nov 14, 2023

Price target increased by 12% to US$17.33

AngioDynamics, Inc. to Report Q1, 2024 Results on Oct 04, 2023

AngioDynamics, Inc. Receives FDA Breakthrough Device Designation for the AngioVac System for the Non-Surgical Removal of Right Heart Vegetation

Angiodynamics, Inc. Completes Enrollment for Preserve Clinical Study

CEO, President & Director exercised options and sold US$102k worth of stock

AngioDynamics, Inc. Announces Addition of Lorinda Burgess to Board of Directors

Consensus EPS estimates fall by 52%, revenue upgraded

AngioDynamics, Inc. Provides Financial Guidance for the Fiscal Year 2024

No longer forecast to breakeven

Full year 2023 earnings: EPS misses analyst expectations

AngioDynamics, Inc. to Report Q4, 2023 Results on Jul 12, 2023

New minor risk - Profitability

Merit Medical Systems, Inc. (NasdaqGS:MMSI) acquired Dialysis Product Portfolio and BioSentry Product of AngioDynamics, Inc. (NasdaqGS:ANGO) for $100 million.

Forecast to breakeven in 2026

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

AngioDynamics (NASDAQ:ANGO) Is Carrying A Fair Bit Of Debt

Price target decreased by 22% to US$20.00

Key Executive recently sold US$60k worth of stock

Price target decreased to US$24.00

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

AngioDynamics, Inc. Reaffirms Revenue Guidance for Fiscal 2023

AngioDynamics, Inc. to Report Q2, 2023 Results on Jan 05, 2023

Price target decreased to US$26.50

Insufficient new directors

AngioDynamics, Inc. Announces First Patient Enrolled in APEX-AV Study Assessing AlphaVac F1885 PE System in Treatment of Pulmonary Embolism

CEO, President & Director recently bought US$150k worth of stock

First quarter 2023 earnings: EPS and revenues miss analyst expectations

AngioDynamics, Inc. Reaffirms Earnings Guidance for the Year 2023

AngioDynamics Non-GAAP EPS of -$0.06 misses by $0.04, revenue of $81.5M misses by $1.93M, reaffirms FY guidance

AngioDynamics: Lack Of Upside Capture Remains, Continue To Hold

AngioDynamics, Inc., Annual General Meeting, Nov 03, 2022

AngioDynamics, Inc. to Report Q1, 2023 Results on Oct 06, 2022

Is AngioDynamics (NASDAQ:ANGO) Using Debt In A Risky Way?